RGEN Repligen Corporation

RGEN Repligen Corporation

Healthcare · Medical Instruments & Supplies

Desk view

Watchinglow conviction
Perspectives Biotech Capital Cycle

Market read

POC $118.13 · VWAP $136.68 · +23.7% vs 12m avg buyer

uptrend vol: compressedgaps: stablechurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

1 related perspective

Watchlists @biotech-capital-cycle

RGEN Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist RGEN belongs to, members best 30-day change first — RGEN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@biotech-capital-cycle
View watchlist →
ABCL+73.1% -1.6%1d +19.9%7d TXG+32.6% +3.4%1d -1.1%7d TWST+32.6% +4.9%1d -0.3%7d CRL+27.8% +2.4%1d +3.4%7d ALMR+23.8% -3.1%1d +14.8%7d AVTR+21.9% -1.2%1d -1.6%7d IQV+17.0% +1.9%1d -0.2%7d GENB+15.7% +0.3%1d +6.6%7d CERT+15.4% 0.0%1d -0.9%7d RGEN+14.8% +1.3%1d +3.6%7d SDGR+13.6% -1.1%1d -7.4%7d A+12.9% -0.1%1d -0.2%7d ABSI+11.3% +0.7%1d +2.5%7d MEDP+11.0% +3.2%1d -0.9%7d WAT+10.5% -1.1%1d -1.0%7d TMO+10.0% -0.5%1d -2.3%7d MTD+8.2% -0.1%1d -0.6%7d RXRX+5.8% -1.6%1d -5.2%7d RVTY+5.5% -0.6%1d +0.1%7d ILMN+3.5% +1.2%1d +0.7%7d XBI+3.4% +1.4%1d +1.0%7d FTRE+1.9% +4.0%1d -4.6%7d SLP+0.7% +0.1%1d +0.1%7d ICLR-0.3% +3.9%1d +2.0%7d DHR-0.6% +0.1%1d -3.2%7d BRKR-1.0% -0.1%1d +2.4%7d TEM-1.6% -0.9%1d -6.2%7d SEER-6.5% -2.4%1d -5.5%7d VKTX-9.3% +1.3%1d -2.2%7d QSI-9.8% 0.0%1d -6.3%7d DNA-12.5% +1.9%1d -9.4%7d AGIO-15.1% +0.2%1d +3.1%7d PACB-16.0% +5.2%1d +4.3%7d LAB-23.6% -4.2%1d -11.5%7d QTRX-24.6% +12.7%1d +21.2%7d CDXS-29.0% +1.9%1d +7.4%7d NAUT-49.4% -1.1%1d +2.3%7d

Next earnings RGEN reports in 77 days Nov 3

Against street estimates

How RGEN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 9 quarters · newest report Jul 28 · projection Aug 17

Result
Jul 28 0.450.54+20.4%Beat
May 5 0.390.48 GAAP ≠ +22.9%Beat
Feb 24 0.440.49+10.4%Beat
Oct 28 '25 0.410.46 GAAP ≠ +10.9%Beat
Jul 29 '25 0.390.37 GAAP ≠ -5.0%Miss
Apr 29 '25 0.350.39 GAAP ≠ +11.4%Beat
Feb 20 '25 0.410.44+7.9%Beat
Nov 12 '24 0.330.43 GAAP ≠ +29.4%Beat

News (last pull)

Headlines about RGEN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 58 days ago · Jun 21 · last pull reported an error, so these may be older than they look

RGEN research tape

6 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.

earnings RGEN earnings — 2026-08-04 earnings RGEN earnings — 2026-07-28 candidate MRNA — candidate.roundup candidate MRNA — candidate.roundup deep dive RGEN — Deep Dive (Repligen)
Types
Aug 4 Catalyst RGEN earnings
RGEN
Jul 28 Catalyst RGEN earnings
RGEN
Jun 26 Update MRNA — candidate.roundup
MRNABEAMNTLAINCYKYMRVKTXXBITWST +1 more
Jun 25 Update MRNA — candidate.roundup
MRNABEAMNTLAINCYKYMRVKTXXBITWST +1 more
Jun 4 Deep Dive RGEN (Repligen)
RGEN#biotech-capital-cycle
Feb 26 Scan Biotech Scan
ALNYAMGNBEAMBIIBBNTXCRSPDXCMEDIT +4 more